Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial

BACKGROUND: Ilorasertib (ABT-348) inhibits Aurora and VEGF receptor (VEGFR) kinases. Patients with advanced solid tumours participated in a phase 1 dose-escalation trial to profile the safety, tolerability, and pharmacokinetics of ilorasertib. METHODS: Ilorasertib monotherapy was administered at 10–...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Br J Cancer
Autori principali: Maitland, Michael L., Piha-Paul, Sarina, Falchook, Gerald, Kurzrock, Razelle, Nguyen, Ly, Janisch, Linda, Karovic, Sanja, McKee, Mark, Hoening, Elizabeth, Wong, Shekman, Munasinghe, Wijith, Palma, Joann, Donawho, Cherrie, Lian, Guinan K., Ansell, Peter, Ratain, Mark J., Hong, David
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group UK 2018
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5931107/
https://ncbi.nlm.nih.gov/pubmed/29551775
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0020-2
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi